Ofosu F A, Hirsh J, Esmon C T, Modi G J, Smith L M, Anvari N, Buchanan M R, Fenton J W, Blajchman M A
Canadian Red Cross Society, Hamilton, Ont.
Biochem J. 1989 Jan 1;257(1):143-50. doi: 10.1042/bj2570143.
We have proposed previously that the steps in coagulation most sensitive to inhibition by heparin are the thrombin-dependent amplification reactions, and that prothrombinase is formed in heparinized plasma only after Factor Xa activates Factor VIII and Factor V. These propositions were based on the demonstration that both heparin and Phe-Pro-Arg-CH2Cl completely inhibited 125I-prothrombin activation for up to 60 s when contact-activated plasma (CAP) was replenished with Ca2+. Furthermore, the addition of thrombin to CAP before heparin or Phe-Pro-Arg-CH2Cl completely reversed their inhibitory effects. Additional support for the above hypotheses is provided in this study by demonstrating that, when the activity of thrombin is suppressed by heparin (indirectly) or by Phe-Pro-Arg-CH2Cl (directly), exogenous Factor Xa reverses the ability of these two agents to inhibit prothrombin activation. Prothrombin activation was initiated by adding Factor Xa (1 nM) or thrombin (1 or 10 nM) simultaneously with CaCl2 to CAP. In the absence of heparin or Phe-Pro-Arg-CH2Cl, prothrombin activation was seen 15 s later in either case. Heparin failed to delay, and Phe-Pro-Arg-CH2Cl delayed for 15 s, prothrombin activation in CAP supplemented with Factor Xa. In contrast, heparin and Phe-Pro-Arg-CH2Cl completely inhibited prothrombin activation for at least 45 s in CAP supplemented with 1 nM-thrombin. Heparin failed to delay prothrombin activation in CAP supplemented with 10 nM-thrombin, whereas Phe-Pro-Arg-CH2Cl completely inhibited prothrombin activation in this plasma for 45 s. These results suggest that in CAP: (1) Factor Xa can effectively activate Factor VIII and Factor V when the proteolytic activity of thrombin is suppressed; (2) heparin-antithrombin III is less able to inhibit Factor Xa than thrombin; (3) suppression of the thrombin-dependent amplification reactions is the primary anticoagulant effect of heparin.
我们之前曾提出,凝血过程中对肝素抑制作用最敏感的步骤是凝血酶依赖性放大反应,并且只有在因子Xa激活因子VIII和因子V后,凝血酶原酶才会在肝素化血浆中形成。这些观点基于以下证明:当用Ca2+补充接触激活血浆(CAP)时,肝素和苯丙氨酸-脯氨酸-精氨酸-CH2Cl在长达60秒的时间内完全抑制125I-凝血酶原的激活。此外,在加入肝素或苯丙氨酸-脯氨酸-精氨酸-CH2Cl之前向CAP中加入凝血酶可完全逆转它们的抑制作用。本研究通过证明当凝血酶活性被肝素(间接)或苯丙氨酸-脯氨酸-精氨酸-CH2Cl(直接)抑制时,外源性因子Xa可逆转这两种药物抑制凝血酶原激活的能力,为上述假设提供了额外支持。通过将因子Xa(1 nM)或凝血酶(1或10 nM)与CaCl2同时加入到CAP中来启动凝血酶原激活。在没有肝素或苯丙氨酸-脯氨酸-精氨酸-CH2Cl的情况下,两种情况下15秒后均可见凝血酶原激活。在补充了因子Xa的CAP中,肝素未能延迟凝血酶原激活,而苯丙氨酸-脯氨酸-精氨酸-CH2Cl延迟了15秒。相反,在补充了1 nM-凝血酶的CAP中,肝素和苯丙氨酸-脯氨酸-精氨酸-CH2Cl至少45秒完全抑制凝血酶原激活。在补充了10 nM-凝血酶的CAP中,肝素未能延迟凝血酶原激活,而苯丙氨酸-脯氨酸-精氨酸-CH2Cl在这种血浆中完全抑制凝血酶原激活45秒。这些结果表明,在CAP中:(1)当凝血酶的蛋白水解活性被抑制时,因子Xa可有效激活因子VIII和因子V;(2)肝素-抗凝血酶III抑制因子Xa的能力低于凝血酶;(3)抑制凝血酶依赖性放大反应是肝素的主要抗凝作用。